Company logo

CYCN - Cyclerion Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Cambridge, United States
Type: Equity

CYCN price evolution
CYCN
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Current assets
Cash $20.41 $30.32 $41.13 $53.96
Short term investments
Net receivables $0.23 $0.23 $0.23 $0.1
Inventory
Total current assets $21.66 $31.68 $42.84 $55.46
Long term investments
Property, plant & equipment $1.26 $1.31 $1.37 $1.47
Goodwill & intangible assets
Total noncurrent assets $3.4 $3.53 $3.69 $3.87
Total investments
Total assets $25.05 $35.21 $46.52 $59.33
Current liabilities
Accounts payable $1.65 $2.77 $2.52 $1.83
Deferred revenue
Short long term debt
Total current liabilities $8.53 $9.85 $9.49 $11.09
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $8.53 $9.85 $9.49 $11.09
Shareholders' equity
Retained earnings -$251.94 -$241.44 -$228.05 -$215.08
Other shareholder equity -$0.03 -$0.03 -$0.02 -$0.02
Total shareholder equity $16.52 $25.36 $37.03 $48.25
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $53.96 $54.4 $94.89
Short term investments
Net receivables $0.1 $0.13 $1.47
Inventory
Total current assets $55.46 $58.5 $101.2 $0.88
Long term investments $3.84 $4.99
Property, plant & equipment $1.47 $50.27 $79.75 $6.5
Goodwill & intangible assets
Total noncurrent assets $3.87 $56.88 $85.28 $6.52
Total investments $3.84 $4.99
Total assets $59.33 $115.38 $186.48 $7.4
Current liabilities
Accounts payable $1.83 $1.44 $3.31 $2.78
Deferred revenue
Short long term debt $6.8 $3.42
Total current liabilities $11.09 $16.95 $18.25 $17.85
Long term debt $38.93 $70.5
Total noncurrent liabilities $38.93 $70.5
Total debt $45.73 $73.92
Total liabilities $11.09 $55.88 $88.75 $17.85
Shareholders' equity
Retained earnings -$215.08 -$163.43 -$85.63
Other shareholder equity -$0.02 -$0.03 -$0.02 -$10.45
Total shareholder equity $48.25 $59.49 $97.73 -$10.45
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Revenue
Total revenue $0.31 $0.71 $0.53
Cost of revenue
Gross Profit $0.31 $0.71 $0.53
Operating activities
Research & development $7.08 $10.22 $9.74 $10.46
Selling, general & administrative $3.52 $3.52 $3.95 $4.41
Total operating expenses $10.61 $13.74 $13.7 $14.87
Operating income -$10.61 -$13.43 -$12.98 -$14.34
Income from continuing operations
EBIT -$10.61 -$13.43 -$12.98 -$10.77
Income tax expense
Interest expense -$0.11 -$0.04 -$0.01 $0
Net income
Net income -$10.5 -$13.39 -$12.98 -$10.78
Income (for common shares) -$10.5 -$13.39 -$12.98 -$10.78
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $3.94 $2.3 $4.51
Cost of revenue
Gross Profit $3.94 $2.3 $4.51
Operating activities
Research & development $37.64 $56.41 $95.14 $87.72
Selling, general & administrative $20.62 $28.82 $34.4 $27.54
Total operating expenses $59.14 $83.56 $129.54 $115.25
Operating income -$55.2 -$81.27 -$125.04 -$115.25
Income from continuing operations
EBIT -$51.63 -$77.8 -$123.01 -$115.25
Income tax expense
Interest expense $0.02
Net income
Net income -$51.65 -$77.8 -$123.01 -$115.25
Income (for common shares) -$51.65 -$77.8 -$123.01 -$115.25
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Net income -$10.5 -$13.39 -$12.98 -$10.78
Operating activities
Depreciation $0.02 $0.05 $0.05
Business acquisitions & disposals
Stock-based compensation $1.66 $1.7 $1.77 $2.55
Total cash flows from operations -$9.91 -$10.82 -$12.84 -$8.63
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $0.02 $0.09
Net borrowings
Total cash flows from financing $0.02 $0.09
Effect of exchange rate -$0 -$0 -$0 $0
Change in cash and equivalents -$9.92 -$10.8 -$12.84 -$8.54
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$51.65 -$77.8 -$123.01 -$115.25
Operating activities
Depreciation $0.47 $2.3 $2.7 $1.53
Business acquisitions & disposals
Stock-based compensation $9.61 $14.99 $19.63 $12.43
Total cash flows from operations -$36.52 -$72.49 -$102.22 -$97.5
Investing activities
Capital expenditures $1.46 $0.02 -$6.71 -$3.44
Investments
Total cash flows from investing $1.46 $0.02 -$6.71 -$3.44
Financing activities
Dividends paid
Sale and purchase of stock $30.79 $24.58 $175.51
Net borrowings $3.51
Total cash flows from financing $30.79 $28.09 $211.57 $100.94
Effect of exchange rate $0 -$0.01 -$0.02
Change in cash and equivalents -$4.27 -$44.39 $102.62
Fundamentals
Market cap $34.23M
Enterprise value $13.82M
Shares outstanding 43.49M
Revenue $1.55M
EBITDA -$47.69M
EBIT -$47.80M
Net Income -$47.64M
Revenue Q/Q -100.00%
Revenue Y/Y -56.25%
P/E ratio -0.72
EV/Sales 8.92
EV/EBITDA -0.29
EV/EBIT -0.29
P/S ratio 22.08
P/B ratio 2.07
Book/Share 0.38
Cash/Share 0.47
EPS -$1.10
ROA -114.70%
ROE -149.84%
Debt/Equity 0.23
Net debt/EBITDA 0.25
Current ratio 2.54
Quick ratio 2.54